- Home
- FFA vs SIGA Comparison
FFA vs SIGA Comparison
Compare FFA & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- SIGA
- Stock Information
- Founded
- FFA 2004
- SIGA 1995
- Country
- FFA United States
- SIGA United States
- Employees
- FFA N/A
- SIGA N/A
- Industry
- FFA Investment Managers
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- SIGA Health Care
- Exchange
- FFA Nasdaq
- SIGA Nasdaq
- Market Cap
- FFA 400.0M
- SIGA 422.9M
- IPO Year
- FFA N/A
- SIGA 1997
- Fundamental
- Price
- FFA $19.90
- SIGA $6.12
- Analyst Decision
- FFA
- SIGA
- Analyst Count
- FFA 0
- SIGA 0
- Target Price
- FFA N/A
- SIGA N/A
- AVG Volume (30 Days)
- FFA 26.1K
- SIGA 410.3K
- Earning Date
- FFA 01-01-0001
- SIGA 07-31-2025
- Dividend Yield
- FFA 6.72%
- SIGA 9.80%
- EPS Growth
- FFA N/A
- SIGA N/A
- EPS
- FFA N/A
- SIGA 0.67
- Revenue
- FFA N/A
- SIGA $120,330,310.00
- Revenue This Year
- FFA N/A
- SIGA N/A
- Revenue Next Year
- FFA N/A
- SIGA $95.31
- P/E Ratio
- FFA N/A
- SIGA $9.12
- Revenue Growth
- FFA N/A
- SIGA N/A
- 52 Week Low
- FFA $15.84
- SIGA $4.95
- 52 Week High
- FFA $19.30
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- FFA 59.54
- SIGA 49.66
- Support Level
- FFA $19.78
- SIGA $5.86
- Resistance Level
- FFA $20.05
- SIGA $6.63
- Average True Range (ATR)
- FFA 0.16
- SIGA 0.25
- MACD
- FFA -0.03
- SIGA 0.00
- Stochastic Oscillator
- FFA 62.58
- SIGA 33.77
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.